Results 1 to 10 of about 21,874 (160)
Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib [PDF]
Frontiers in PharmacologyHER2 is amplified in approximately 20% of gastric cancers, and these patients exhibit a favorable response to trastuzumab treatment. Lapatinib, as a HER2-targeted drug, demonstrates potent inhibitory effects on HER2-addicted N87 gastric cancer cells ...
Xiaochen Ni +15 more
doaj +2 more sources
Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study [PDF]
PeerJ, 2023 Background Lapatinib is an oral small-molecule tyrosine kinase inhibitor indicated for advanced or metastatic HER2-positive breast cancer. In order to reduce the treatment cost, a high-fat enteral nutrition emulsion TPF-T was selected as a dose-sparing ...
Junfeng Zhu +7 more
doaj +2 more sources
Reactions Weekly, 2009 The human epidermal growth factor receptor (HER) family of growth factor receptor tyrosine kinases (RTKs) plays an important role in the biology of many cancers. In breast cancer, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival. Patients overexpressing HER2 have a poor prognosis, which can be
Schneider-Merck, Tanja, Trepel, Martin
+5 more sources
Heliyon, 2022 The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect
Ziyin Tian +11 more
doaj +1 more source
Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. [PDF]
PLoS ONE, 2011 Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her) in solid tumors. Little is known about the effect of lapatinib on leukemia.
Huey-Lan Huang +6 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance.
Min Ye +11 more
doaj +1 more source
Frontiers in Pharmacology, 2020 The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation
Noëmi Johanna Roos +10 more
doaj +1 more source
Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
Scientific Reports, 2022 Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2.
Shingo Maeda +7 more
doaj +1 more source
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
PLoS ONE, 2021 Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gene ...
Jason J Zoeller +6 more
doaj +1 more source
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
PLoS ONE, 2011 BackgroundOverexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.
Rama Krishna Kancha +5 more
doaj +1 more source